Medico-economic Evaluation of ENTERRA Therapy (ENTERRA)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this clinical trial is to assess the symptomatic efficacy and the impact on the utilization of healthcare resources of a treatment by gastric electrical stimulation (ENTERRA ®) in patients with refractory nausea and/or vomiting leading to a nutritional impairment. Eligible patients will be those with refractory symptoms either idiopathic, postsurgical or due to diabetes mellitus. The duration of the study will be 28 months for each patient.
After a run-in period of 4 months during which a prospective assessment of healthcare resources utilization and of the severity of the symptoms will be obtained, patients will be implanted. The follow-up period after implantation of the device will last 24 months in every patients and will be divided in two parts: a) After the first postoperative month during which the device will remained on the "OFF" position, the first phase of the study will be a randomized double-blind cross-over study with 2 periods of 4 months during which the device will be activated or not. After the 9th month of follow up, the trial will be an open trial and the device will be activated in all patients.
During the whole trial, patients will record all types of healthcare resources utilizations (hospitalizations, drug treatments, endoscopic procedures…) while the symptomatic efficacy of the treatment will be assessed by standard questionnaires at the following visits scheduled at 1, 5, 9, 12, 18, 24 months. The glycemic control will be determined at each visit in diabetic patients. A delayed gastric emptying will not be a selection criteria but we have planned to analyze the clinical results of the treatment in taking into account a delayed or normal gastric emptying during the pre-implantation period. Moreover, gastric emptying studies have been scheduled at 5, 9, 12 and 24 months to test the impact of gastric electrical stimulation on gastric emptying.
| Condition | Intervention |
|---|---|
|
Gastroparesis Vomiting Nausea |
Device: Implantation of ENTERRA therapy |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Clinical Efficacy and Efficiency of Gastric Electrical Stimulation (Enterra®) for Refractory Nausea and/or Vomiting |
- clinical efficacy [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- medico-economic evaluation of ENTERRA therapy [ Time Frame: 28 months ] [ Designated as safety issue: No ]
| Enrollment: | 220 |
| Study Start Date: | June 2009 |
| Study Completion Date: | November 2015 |
| Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months. After the cross-over period, device activated until the end of the trial |
Device: Implantation of ENTERRA therapy
Gastric electrical stimulation using Enterra Therapy
|
|
2
Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months. After the cross-over period, device activated until the end of the trial |
Device: Implantation of ENTERRA therapy
Gastric electrical stimulation using Enterra Therapy
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Nausea and/or vomiting refractory to prokinetics and antiemetics fulfilling the following criteria
- Due to diabetes mellitus type 1, secondary to oesogastric surgery (vagotomy, partial gastric resection) or idiopathic
- Non related to other cause
- Chronic (duration > 12 months)
- Occurring at least weekly
- Refractory to anti-emetics (chlorpromazine, ondansétron, granisétron) and/or prokinetics (domperidone, metoclopramide, erythromycin),
- Leading to weight loss or significant reduction of food intake
- occurring in patients without any contra-indication for the surgical implantation of the device, in particular severe cardiac or respiratory failure or haemostasis disorders,
- in patients older than 18 years
- with a negative pregnancy test at entry into the trial in women
- Patients who signed the study consentment
- Affiliation to the the welfare system
Exclusion Criteria:
- Patients older than 70,
- Patients in whom nausea and/or vomiting are related to another aetiology than that previously described.
- Patients with an absolute contraindication for general anaethesia and surgery
- Patients with a contra-indication for implantation of the device
- Patients with a severe psychiatric disorder
- Patients under guardianship or curatorship
- Patients with a major obesity or as severe eating disorder.
- Patients unable to understand French.
- Pregnant women or nursing mothers
- Lack of effective contraception
- Patients having undergone a pancreatic graft within the previous 6 months and being in a unstable clinical conditions at enrollment
- Patients with an underlying disease leading to a follow-up by MRI
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00903799
| France | |
| UH Besancon | |
| Besancon, France, 25030 | |
| AP-HP Jean Verdier | |
| Bondy, France, 93143 | |
| UH Bordeaux | |
| Bordeaux, France, 33076 | |
| UH Clermont Ferrand | |
| Clermont Ferrand, France, 63000 | |
| AP-HP Louis Mourier | |
| Colombes, France, 92071 | |
| Corbeil Essones Hospital | |
| Corbeil-Essonnes, France, 91106 | |
| UH Grenoble | |
| Grenoble, France, 38043 | |
| UH Lille | |
| Lille, France, 59000 | |
| UH Lyon | |
| Lyon, France, 69000 | |
| UH Marseille | |
| Marseille, France, 13000 | |
| UH Montpellier | |
| Montpellier, France, 34000 | |
| UH Nancy | |
| Nancy, France, 54000 | |
| UH Nantes | |
| Nantes, France, 44000 | |
| UH Nice | |
| Nice, France, 06202 | |
| UH Nimes | |
| Nimes, France, 30029 | |
| UH Poitiers | |
| Poitiers, France, 86021 | |
| UH Rennes | |
| Rennes, France, 35033 | |
| UH Rouen | |
| Rouen, France, 76031 | |
| UH Strasbourg | |
| Strasbourg, France, 67091 | |
| UH Toulouse | |
| Toulouse, France, 31075 | |
| UH Tours | |
| Tours, France, 37044 | |
| Principal Investigator: | Philippe DUCROTTE, Pr | UH Rouen |
More Information
| Responsible Party: | University Hospital, Rouen |
| ClinicalTrials.gov Identifier: | NCT00903799 History of Changes |
| Other Study ID Numbers: | 2008/046/HP |
| Study First Received: | May 14, 2009 |
| Last Updated: | May 25, 2016 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Rouen:
|
Drug-refractory gastroparesis diabetes mellitus induced gastroparesis Gastric electrical stimulation Long-term multicenter study |
Additional relevant MeSH terms:
|
Nausea Vomiting Gastroparesis Signs and Symptoms, Digestive Signs and Symptoms |
Stomach Diseases Gastrointestinal Diseases Digestive System Diseases Paralysis Neurologic Manifestations |
ClinicalTrials.gov processed this record on September 23, 2016